Harmony Biosciences Holdings (Harmony Biosciences Holdings) Market Cap : $1,796.7 Mil (As of Apr. 30, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Harmony Biosciences Holdings Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Harmony Biosciences Holdings's share price for the quarter that ended in Dec. 2023 was $32.3. Harmony Biosciences Holdings's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 56.8 Mil. Therefore, Harmony Biosciences Holdings's market cap for the quarter that ended in Dec. 2023 was $1,833.6 Mil.

Harmony Biosciences Holdings's quarterly market cap declined from Jun. 2023 ($2,111.4 Mil) to Sep. 2023 ($1,919.4 Mil) and declined from Sep. 2023 ($1,919.4 Mil) to Dec. 2023 ($1,833.6 Mil).

Harmony Biosciences Holdings's annual market cap increased from Dec. 2021 ($2,508.3 Mil) to Dec. 2022 ($3,284.8 Mil) but then declined from Dec. 2022 ($3,284.8 Mil) to Dec. 2023 ($1,833.6 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Harmony Biosciences Holdings's Enterprise Value for Today is $1,636.8 Mil.

Harmony Biosciences Holdings Market Cap Historical Data

The historical data trend for Harmony Biosciences Holdings's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harmony Biosciences Holdings Market Cap Chart

Harmony Biosciences Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Market Cap

Get a 7-Day Free Trial

2,056.60

2,508.33

3,284.83

1,833.64

Harmony Biosciences Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Market Cap	Get a 7-Day Free Trial															3,284.83	1,957.52	2,111.39	1,919.40	1,833.64

Competitive Comparison of Harmony Biosciences Holdings's Market Cap

For the Biotechnology subindustry, Harmony Biosciences Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Harmony Biosciences Holdings's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Harmony Biosciences Holdings's Market Cap distribution charts can be found below:

* The bar in red indicates where Harmony Biosciences Holdings's Market Cap falls into.

Harmony Biosciences Holdings Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Harmony Biosciences Holdings's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )	=	Share Price (A: Dec. 2023 )	*	Shares Outstanding (EOP) (A: Dec. 2023 )
	=	$32.3	*	56.7691
	=	$1,833.6

Harmony Biosciences Holdings's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )	=	Share Price (Q: Dec. 2023 )	*	Shares Outstanding (EOP) (Q: Dec. 2023 )
	=	$32.3	*	56.7691
	=	$1,833.6

Harmony Biosciences Holdings (NAS:HRMY) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Harmony Biosciences Holdings Market Cap Related Terms

Thank you for viewing the detailed overview of Harmony Biosciences Holdings's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

Harmony Biosciences Holdings (Harmony Biosciences Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Harmony Biosciences Holdings Inc (NAS:HRMY) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

N/A

Address

630 West Germantown Pike, Suite 215, Plymouth Meeting, PA, USA, 19462

Website

https://www.harmonybiosciences.com

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.

Executives

Peter Anastasiou	director	C/O HARMONY BIOSCIENCES HOLDINGS, INC., 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Jack Nielsen	director	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Andreas Wicki	director	C/O HBM BIOVENTURES (CAYMAN) LTD., CENTENNIAL TOWERS,STE.305,2454 W.BAY RD., GRAND CAYMAN E9 E9
Andrew Serafin	officer: Chief Business Officer	630 W. GERMANTOWN PIKE, PLYMOUTH MEETING PA 19462
Jeffrey M. Dayno	officer: Chief Medical Officer	460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087
Jeffrey Dierks	officer: Chief Commercial Officer	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
John C Jacobs	director, officer: President, CEO	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Linda M Szyper	director	C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 250, SUITE 400, GRAND PRAIRIE TX 75050
Sandip Kapadia	officer: Chief Financial Officer	450 WEST 15 STREET, SUITE 505, NEW YORK NY 10011
R. Mark Graf	director	C/O DISCOVER FINANCIAL SERVICES, 2500 LAKE COOK ROAD, RIVERWOODS IL 60015
Eric L Motley	director	1516 33RD STREET NW, WASHINGTON DC 20007
Valor Equity Partners Iv-a L.p.	10 percent owner	875 NORTH MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611
Valor Equity Partners Iv-b L.p.	10 percent owner	875 NORTH MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611
Marshman Fund Trust Ii	10 percent owner	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Valor Equity Capital Iv Llc	10 percent owner	875 N. MICHIGAN AVENUE, SUITE 3214, CHICAGO IL 60611